Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 9, Number 7, July 2017, pages 567-572


A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes

Figure

Figure 1.
Figure 1. Assessment, randomization, and follow-up of the study patients.

Tables

Table 1. Clinical and Laboratory Characteristics at Baseline, 12 Weeks, and 24 Weeks of Treatment With Vildagliptin or Alogliptin
 
VildagliptinAlogliptin
Baseline12 week24 week
Vildagliptin → sitagliptin
Baseline12 week24 week
Alogliptin → sitagliptin
*P = 0.05, data compared with baseline values using the t-test. †P = 0.05, data compared with 12 weeks values using the t-test.
Age63.2 ± 13.565.1 ± 12.060.4 ± 12.9
Male109
Female97
Height (cm)162.8 ± 10.1159.3 ± 9.5
Weight (kg)65.4 ± 13.368.6 ± 13.267.2 ± 16.359.4 ± 11.260.4 ± 12.960.2 ± 12.1
BMI (kg/m2)24.6 ± 4.423.1 ± 3.5
PG (mg/dL)175.5 ± 54.4179.1 ± 73.4172.2 ± 54.5175.4 ± 50.9195.3 ± 55.0189.3 ± 32.4
HbA1c (%)8.0 ± 0.58.0 ± 0.88.3 ± 0.78.0 ± 0.58.31 ± 0.7*8.0 ± 0.8†

 

Table 2. The Response Rate (RR) of Achieving the Goal Proportion of Patients Who Achieved Target Glycemic Control
 
Alogliptin (N = 16)Vildagliptin (N = 19)P value
Proportion of patients who achieved HbA1c < 7.0% at 12 weeks1 (6.3%)2 (10.5%)1.000
Proportion of patients who achieved PG < 130 mg/dL at 12 weeks1 (6.3)7 (36.8%)0.047
Change to sitagliptin13 (81.2%)15 (78.9%)
Proportion of patients who achieved HbA1c < 7.0% at 24 weeks3 (9.1%)
Proportion of patients who achieved PG < 130 mg/dL at 24 weeks1 (3.0%)